Cognitive and Memory Enhancer Drugs Market
The Global Cognitive and Memory Enhancer Drugs Market Size, Share and Trends Analysis Report, By Product (Aricept, Exelon, Namenda, Razadyne, Provigil, Ritalin, Adderall, and Others), By Application (Disease Treatment (Developmental Conditions, Neurodegenerative Conditions), Academic Performance, and Athletic Performance), Forecast (2022-2028)
The global cognitive and memory enhancer drugs market is projected to expand at a significant CAGR of around 5.5% during the forecast period. Cognitive enhancers are medications and supplements that are primarily used to treat patients with alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. The surge in the geriatric population and the rise in the prevalence of neurological and memory-related disorders are the major factors driving the growth of the global cognitive and memory enhancer drugs market. As per the Family Caregiver Alliance, more than one million adults in the U.S. are diagnosed annually with a chronic brain disease or disorder. Whereas, in 2020, as many as 5.8 million Americans were living with Alzheimer’s disease. This prevalence is leading to the high demand for cognitive and memory enhancer drugs by populations suffering from Alzheimer and other memory-related disease which in turn driving the market growth. Furthermore, the advantages provided by cognitive drugs, such as improved memory and reasoning, drives market growth. However, ethical concerns about the use of these drugs may limit the market growth.
Impact of COVID-19 Pandemic on Global Cognitive and Memory Enhancer Drugs
The global cognitive and memory enhancer drugs market was positively impacted by the COVID-19 pandemic During pandemic, elderly individuals were on high risk of developing severe forms of neuropsychiatric and cognitive impairments. Several reports have described insomnia, depressed mood, anxiety, post-traumatic stress disorder and cognitive impairment in a proportion of patients after discharge from the hospital. Moreover, concerns associated with the hospitalization and mortality due to COVID among populations has put them under depression and due that people were started taking anti-depressant medicines in order to get out of the situation. In patients with dementia, COVID-19 frequently has an atypical presentation with mental status changes complicating the early identification of cases. This led to the demand for cognitive and memory enhancer drugs. ?
Segmental Outlook
The global market for cognitive and memory enhancer drugs is analyzed based on product, and applications.. The product segment is further sub-segmented into sAricept, Exelon, Namenda, Razadyne, Provigil, Ritalin Adderall, and Others. Among these, the Aricept segment contributed highest share to the market growth in 2021, the segment is again going to hold lucrative share to rise in geriatric population and increase in adoption of Aricept for the treatment of neurological disorders. Based on applications, the market is sub-categorized into disease treatment, developmental conditions, neurodegenerative conditions, academic performance, athletic performance, and others.
Global Cognitive and Memory Enhancer Drugs Market, by Application, 2020 (%)
The Disease Treatment Segment is Anticipated to Hold a Prominent Share in the Global Cognitive and Memory Enhancer Drugs
Among application, the disease treatment dominated the market and the segment is again going to maintain its dominance during the forecast period. Rising neurodegenerative disorder such as dementia, Alzheimer’s, stroke, schizophrenia, and ADHD (attention deficit hyperactivity disorder) among population due to change in lifestyle and increase in stress level leading to demand for cognitive and memory enhancer drugs in these diseases treatments. Drugs such as Namenda approvaed by the Food and Drugs Administration's (FDA) for Alzheimer's and dementia, and it aids in slowing the disease's progression. The FDA has approved meantime (Namenda) and a combination of meantime and donepezil (Namzaric) for the treatment of moderate to severe Alzheimer's disease. Namenda regulates the activity of glutamate, a chemical involved in information processing, storage, and retrieval, and it also improves mental function and the ability to perform daily activities in some people. Moreover, the FDA has approved the new psychostimulant modafinil (Provigil) for improving alertness, a critical factor in cognitive performance.
Regional Outlooks
The global cognitive and memory enhancer drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.?
Global Cognitive and Memory Enhancer Drugs Market Growth, by Region 2022-2028
The Asia-Pacific Region is estimated to Hold the Major Share in the Global Cognitive and Memory Enhancer Drugs
The Asia-Pacific region is expected to grow at fastest CAGR during the forecast period, owing to an increase in the geriatric population and a high prevalence of cognitive diseases, particularly in the region's affluent countries. Apart from these, the increase in adoption of natural and herbal products owing to the rising consumer concern about brain health problems like weak memory, & poor concentration is the other prominent factor enhancing the market growth. Moreover, supportive government policies in the healthcare sector and an increasing number of promotional activities by key players will drive the market growth. ?
Market Players Outlook
The key players that provide products are Pfizer Inc., Allergan Plc, Takeda Pharmaceutical Company Limited, Cephalon, (Teva Pharmaceutical Industries Ltd.), Eisai Co., Ltd., Novartis AG, Johnson & Johnson, AlternaScript LLC, and Ceretropic are the major market players. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2022, AbbVie and Gedeon Richter Plc announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. Collaboration with AbbVie will open the way towards new products that could help alleviate the debilitating psychiatric and cognitive symptoms of many neuropsychiatric conditions, leading to an improved quality of life for patients suffering from these conditions.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cognitive and memory enhancer drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Cognitive and Memory Drugs Market
- Recovery Scenario of Global Cognitive and Memory Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Pfizer Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Developments
3.2. Biogen, Inc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Takeda Pharmaceutical Company Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.3.5. Johnson & Johnson Overview
3.3.6. Financial Analysis
3.3.7. SWOT Analysis
3.3.8. Recent Developments
4. Global Cognitive and Memory Enhancer Drugs Market Segmentation
4.1 Global Cognitive and Memory Enhancer Drugs, by Product
4.1.1. Aricept
4.1.2. Exelon
4.1.3. Namenda
4.1.4. . Razadyne
4.1.5. Provigil
4.1.6. Ritalin
4.1.7. Adderall
4.1.8. Others
4.2 Global Cognitive and Memory Enhancer Drugs, by Application
4.1.9. Disease Treatment
4.1.10. Developmental Conditions
4.1.11. Neurodegenerative Conditions
4.1.12. Academic Performance
4.1.13. Athletic Performance
4.1.14. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1 Novartis International AG
6.2 AbbVie
6.3 Eisai Co., Ltd.
6.4 Cephalon, Inc.
6.5 AlternaScript LLC
6.6 Allergan Plc.
6.7 Takeda Pharmaceutical Company
6.8 Torrent Pharmaceuticals
6.9 Alterna Script LLC
6.10 Reckitt Benckiser Group PLC
6.11 Purelife Bioscience Co., Ltd.
6.12 Liquid Health, Inc.
6.13 Onnit Labs, Inc.
6.14 Quincy Bioscience LLC
1. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ARICEPt COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EXELON COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL EXELON COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL NAMENDA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL RAZADYNE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL PROVIGIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RITALIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ADDERALL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL OTHER COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
12. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS FOR DEVELOPMENTAL CONDITION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS FOR NEURODEGENERATIVE CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS FOR ACADEMIC PERFORMANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS FOR ATHLETIC PERFORMANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
19. NORTH AMERICAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. NORTH AMERICAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. NORTH AMERICAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. EUROPEAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. EUROPEAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
24. EUROPEAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
28. REST OF THE WORLD COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. REST OF THE WORLD COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
30. REST OF THE WORLD COGNITIVE AND MEMORY ENHANCER DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, 2022-2028 (%)
4. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ARICEPT COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EXELON COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL NAMENDA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL RAZADYNE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL PROVIGIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL RITALIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL ADDERALL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL OTHER COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
14. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN DEVELOPMENTAL CONDITION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN Neurodegenerative Conditions MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN Academic Performance MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN Athletic Performance MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS IN OTHER APPLICATIONS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
21. US COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
29. INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
30. CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
31. JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
32. SOUTH KOREA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
34. REST OF THE WORLD COGNITIVE AND MEMORY ENHANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
